Literature DB >> 33109354

Hyperprogression in hepatocellular carcinoma: Illusion or reality?

Stephen L Chan1.   

Abstract

Entities:  

Keywords:  Accelerated progression; Hyperprogressive disease; Immunotherapy; Liver neoplasm

Year:  2020        PMID： 33109354     DOI： 10.1016/j.jhep.2020.09.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  4 in total

1.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.

Authors:  Tim F Greten; Ghassan K Abou-Alfa; Ann-Lii Cheng; Austin G Duffy; Anthony B El-Khoueiry; Richard S Finn; Peter R Galle; Lipika Goyal; Aiwu Ruth He; Ahmed O Kaseb; Robin Kate Kelley; Riccardo Lencioni; Amaia Lujambio; Donna Mabry Hrones; David J Pinato; Bruno Sangro; Roberto I Troisi; Andrea Wilson Woods; Thomas Yau; Andrew X Zhu; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

Review 2.  Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?

Authors:  Choong-Kun Lee; Stephen L Chan; Hong Jae Chon
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

3.  Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients.

Authors:  Jixue Zou; Peixin Huang; Ningling Ge; Xin Xu; Yanhong Wang; Lan Zhang; Yi Chen
Journal:  J Gastrointest Oncol       Date:  2022-08

4.  A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.

Authors:  Stephen L Chan; Paul N M Cheng; Angela M Liu; Landon L Chan; Leung Li; Cheuk M Chu; Charing C N Chong; Yat M Lau; Winnie Yeo; Kelvin K C Ng; Simon C H Yu; Tony S K Mok; Anthony W H Chan
Journal:  Invest New Drugs       Date:  2021-04-15       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.